JPWO2021186180A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021186180A5 JPWO2021186180A5 JP2022556583A JP2022556583A JPWO2021186180A5 JP WO2021186180 A5 JPWO2021186180 A5 JP WO2021186180A5 JP 2022556583 A JP2022556583 A JP 2022556583A JP 2022556583 A JP2022556583 A JP 2022556583A JP WO2021186180 A5 JPWO2021186180 A5 JP WO2021186180A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- disease
- formulation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004094.5A GB202004094D0 (en) | 2020-03-20 | 2020-03-20 | New compounds and uses |
| GB2004094.5 | 2020-03-20 | ||
| PCT/GB2021/050674 WO2021186180A1 (en) | 2020-03-20 | 2021-03-18 | Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023518474A JP2023518474A (ja) | 2023-05-01 |
| JPWO2021186180A5 true JPWO2021186180A5 (https=) | 2024-03-28 |
| JP2023518474A5 JP2023518474A5 (https=) | 2024-03-28 |
| JP7773988B2 JP7773988B2 (ja) | 2025-11-20 |
Family
ID=70546543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556583A Active JP7773988B2 (ja) | 2020-03-20 | 2021-03-18 | アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230114153A1 (https=) |
| EP (1) | EP4121047B1 (https=) |
| JP (1) | JP7773988B2 (https=) |
| CN (1) | CN115666557A (https=) |
| CA (1) | CA3174437A1 (https=) |
| GB (1) | GB202004094D0 (https=) |
| WO (1) | WO2021186180A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096883A (en) * | 1933-07-19 | 1937-10-26 | Electrolux Corp | Vacuum cleaner |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| WO1994027597A1 (en) * | 1993-05-21 | 1994-12-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid angiotensin ii receptor antagonists |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| US9864250B2 (en) * | 2014-11-14 | 2018-01-09 | Heliotrope Technologies, Inc. | Post-temperable nanocrystal electrochromic devices |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) * | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| GB202006079D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) * | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2023152503A1 (en) * | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
-
2020
- 2020-03-20 GB GBGB2004094.5A patent/GB202004094D0/en not_active Ceased
-
2021
- 2021-03-18 CN CN202180021097.2A patent/CN115666557A/zh active Pending
- 2021-03-18 US US17/912,645 patent/US20230114153A1/en active Pending
- 2021-03-18 CA CA3174437A patent/CA3174437A1/en active Pending
- 2021-03-18 WO PCT/GB2021/050674 patent/WO2021186180A1/en not_active Ceased
- 2021-03-18 JP JP2022556583A patent/JP7773988B2/ja active Active
- 2021-03-18 EP EP21714661.2A patent/EP4121047B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5941598B2 (ja) | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 | |
| JP2004520292A5 (https=) | ||
| US12458642B2 (en) | Metalloenzyme inhibitor compounds | |
| JP2014500322A5 (https=) | ||
| JP2005538955A5 (https=) | ||
| JP2005511608A5 (https=) | ||
| JP5602230B2 (ja) | スフィンゴシン−１−リン酸受容体アゴニスト | |
| JP2025512995A (ja) | カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 | |
| JP2019522628A5 (https=) | ||
| WO2005080378A1 (ja) | 縮合ピリダジン誘導体 | |
| JP2004525183A5 (https=) | ||
| JP2004532276A5 (https=) | ||
| JP2016510810A5 (https=) | ||
| US10538511B2 (en) | Metalloenzyme inhibitor compounds | |
| JPWO2021186180A5 (https=) | ||
| JPWO2021186185A5 (https=) | ||
| JPWO2021053344A5 (https=) | ||
| JP2006528199A5 (https=) | ||
| JPWO2022049372A5 (https=) | ||
| JPWO2023281271A5 (https=) | ||
| JPWO2022178420A5 (https=) | ||
| JPWO2022200786A5 (https=) | ||
| JPWO2022200785A5 (https=) | ||
| JP2646405B2 (ja) | ビフェニルメタン誘導体カリウム塩及びこれを含有する医薬 | |
| JPWO2021083209A5 (https=) |